Sergio Traversa - 12 Dec 2025 Form 4 Insider Report for RELMADA THERAPEUTICS, INC. (RLMD)

Role
Chief Executive Officer, Director
Signature
/s/ Sergio Traversa
Issuer symbol
RLMD
Transactions as of
12 Dec 2025
Net transactions value
+$113,300
Form type
4
Filing time
16 Dec 2025, 09:30:49 UTC
Previous filing
06 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
TRAVERSA SERGIO Chief Executive Officer, Director C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES /s/ Sergio Traversa 16 Dec 2025 0001565832

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLMD Common Stock Purchase $113,300 +27,500 +2.2% $4.12 1,300,000 15 Dec 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RLMD Stock Appreciation Rights Award $0 +1,198,000 $0.000000 1,198,000 12 Dec 2025 Common Stock 1,198,000 $4.06 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
F2 Purchase prices range from $4.10 to $4.12 per share, inclusive.
F3 The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026.